Key result
Combined modality therapy linked to improved overall survival in patients with angiosarcoma.
Why the study?
Does combined modality therapy improve overall survival in patients with angiosarcoma?
Does combined modality therapy improve overall survival in patients with angiosarcoma?
Combined modality therapy may improve overall survival in patients with angiosarcoma.
Metastatic presentation and older age were associated with worse angiosarcoma survival; leaves open need for multi-institutional data to refine management.
Angiosarcomas are rare, aggressive malignancies of endothelial origin that account for 1 to 4% of all soft tissue sarcomas [1,2]. Though these tumors can occur at any soft tissue site, 60% arise in...
No takes yet. Share an insight, caveat, or question.
Shen et al. (2017) studied this question. Combined modality therapy improves overall survival in patients with angiosarcoma.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: